Clinical Trial Update: A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the photoallergic potential of PEP005 (ingenol mebutate) gel 0.01% in healthy volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• PEP005 (ingenol mebutate) gel 0.01% (ingenol mebutate)

Snippet

Sponsor: Peplin | Conditions: Actinic Keratosis | Phase 1 | Status: COMPLETED